VivaGel BV treatment clinical submission under rolling NDA
Filed with ASX · · 3 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- NDA submission for VivaGel BV in the US
- VivaGel BV granted marketing approval in Australia
- Starpharma and Peter Mac Cancer Centre awarded DEP Grant
- AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor
- DEP docetaxel positive phase 1 results, phase 2 commences
Later from Starpharma
- Starpharma to commence DEP cabazitaxel phase 1/2 trial
- Starpharma receives $3.7M R&D tax incentive refund
- Starpharma completes US New Drug Application for VivaGel BV
- Appendix 4C - Quarterly Cashflow Report
- Mundipharma licenses Starpharmas VivaGel BV
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma